This study examines a gene therapy called AAV5-RPGR in males with X-linked retinitis pigmentosa. It was designed for male patients aged 5 and over whose diagnosis was confirmed by a retinal specialist. The study was conducted in Phase 1/Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Key inclusion Criteria: * Males aged 5 years or older * Have X-linked retinitis pigmentosa confirmed by a retinal specialist (CI or PI) Key exclusion Criteria: • Have participated in another research study involving an investigational medicinal therapy for ocular disease within the last 6 months